Canaccord analyst Edward Nash raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $420 from $394 and keeps a Buy rating on the shares. The firm said they reported financial results and business highlights for Q1. Product sales of Rezdiffra beat expectations for both the firm and the Street.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals Reports Strong Q1 2025 Results
- Madrigal’s Earnings Call: Rezdiffra’s Success and Future Plans
- Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- Madrigal Pharmaceuticals reports Q1 EPS ($3.32), consensus ($3.79)
- Madrigal Pharmaceuticals announces six presentations at EASL Congress